Clinical Efficacy of Modified Shengyutang in Treatment of Active Stage Psoriasis Vulgaris due to Qi and Blood Deficiency
10.13422/j.cnki.syfjx.20202322
- VernacularTitle:圣愈汤加味治疗进行期寻常型银屑病气血两虚证的临床观察
- Author:
Yuan-yuan LI
1
;
Shi-yu WANG
1
;
Bu-xin ZHANG
1
;
Sheng-dong XU
1
;
Bing-ying HAN
1
;
Ai-min LIU
1
Author Information
1. Henan University of Chinese Medicine， Zhengzhou 450002， China
- Publication Type:Research Article
- Keywords:
modified Shengyutang;
active stage;
psoriasis vulgaris;
Qi and blood deficiency
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(2):87-92
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the clinical efficacy of modified Shengyutang on patients with active stage psoriasis vulgaris due to Qi and blood deficiency. Method:The 134 cases were randomly divided into control group and observation group， with 67 cases in each group. The control group was given avic a capsule + Danggui Buxuewan， while the observation group was given avic a capsule + modified Shengyutang for 4 weeks， respectively. The psoriasis area and severity index （PASI）， dermatological life quality index （DLQI） and psoriasis vulgaris due to Qi and blood deficiency syndrome were observed before and after treatment. The serum growth factor ［endothelial cell specific molecule-1 （ESM-1）， transforming growth factor-β1（TGF-β1）， vascular endothelial cell growth factor （VEGF）］， hemorheological indicators ［high cut blood viscosity （HBV）， low cut blood viscosity （LBV）， erythrocyte sedimentation rate （ESR）］， CC cphenotype receptor（CCR）6， CC cphenotype ligand 20 （CCL20）， monocyte chemotactic protein-4 （MCP-4） in serum and tissue fluid of lesions were detected. Clinical efficacy and recurrence follow-up for 12 months were compared. The safety was evaluated between two groups. Result:Three cases in control group and one case in observation group fell off during the study period. The total effective rate was 96.97% （64/66） in observation group， which was higher than 81.25% （52/64） in control group （χ2=5.064， P<0.05）. During the 12-month follow-up， the recurrence rate was 20.31% （13/64） in observation group， which was lower than 51.92% （27/52） in control group （χ2=6.038， P<0.05）. Compared with control group after treatment， PASI， DLQI， TCM syndromes， ESM-1， TGF-β1， VEGF， HBV， LBV， ESR， CCR6， CCL20 and MCP-4 in observation group were significantly reduced （P<0.05）. No obvious blood and urine routine， or heart， liver and renal dysfunction was observed in the two groups. The incidence of adverse reactions was 3.03% （2/66） in observation group， which was lower than 26.56% （17/64） in control group （χ2=5.764， P<0.05）. Conclusion:Modified Shengyutang can significantly improve the clinical symptoms of patients with active stage psoriasis vulgaris due to Qi and blood deficiency， with a low recurrence rate and the incidence of adverse reactions.
